# Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer

> **NCT00846612** · PHASE1 · COMPLETED · sponsor: **NYU Langone Health** · enrollment: 15 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Doxil
- **DRUG:** Bevacizumab (Avastin)

## Key facts

- **NCT ID:** NCT00846612
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2010-09
- **Final completion:** 2012-06
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2019-09-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00846612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00846612, "Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00846612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*